Objective To investigate the effects of low-frequency repetitive transcranial magnetic stimulation combined with pramipexole on cognitive function and oxidative stress in patients with Parkinson’s disease. Methods Eighty-six patients with Parkinson’s disease admitted to a hospital in Hebi from September 2018 to December 2020 were selected as study subjects and divided into control and observation groups

43 cases each

using the random number table method. The patients in the control group were given low-frequency repetitive transcranial magnetic stimulation treatment

and the observation group was given low-frequency repetitive transcranial magnetic stimulation combined with pramipexole treatment

both groups treated continuously for 1 month. The Montreal Cognitive Assessment（Mo CA） scores

Motor Dysfunction Rating Scale for Parkinson’s Disease（MDRSPD） scores

muscle strength scores

plasma malondialdehyde（MDA） levels

glutathione-peroxidase（GSH-PX） levels

and superoxide dismutase（SOD） levels before and after treatment were compared between the two groups

and the occurrence of adverse effects was compared between the two groups. Results Before treatment

there was no statistically significant difference in Mo CA

MDR-SPD

and muscle strength scores between the 2 groups of patients（P >0.05）. After treatment

the Mo CA and muscle strength scores of the 2 groups were higher than before treatment and higher in the observation group than in the control group

with statistically significant differences（P<0.05）; the MDR-SPD scores were lower than before treatment and lower in the observation group than in the control group

with statistically significant differences（P<0.05）. Before treatment

there was no statistically significant difference between the levels of MDA

GSH-PX and SOD in the 2 groups（P>0.05）. After treatment

the MDA levels of patients in the 2 groups were lower than those before treatment and lower in the observation group than in the control group

with statistically significant differences（P<0.05）; the GSH-PX and SOD levels were higher than before treatment and higher in the observation group than in the control group

with statistically significant differences（P<0.05）. The incidence of adverse reactions was 6.98% in the observation group

which was lower than that of 13.95% in the control group

and the difference was not statistically significant（P>0.05）. Conclusion Low-frequency repetitive transcranial magnetic stimulation combined with pramipexole therapy significantly improves cognitive and motor functions and reduces oxidative stress in patients with Parkinson’s disease

and the safety is relatively high;it is worth promoting in clinical application.